Epithalon

Origin and structure

Epitalon is a chain of four amino acids, alanine, glutamic acid, aspartic acid and glycine (Ala-Glu-Asp-Gly, or AEDG), with the formula C14H22N4O9 and a molar mass of 390.35 g/mol. Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology designed it from the amino-acid make-up of epithalamin, a mixture of peptides extracted from the pineal glands of cattle. The group also tested it on the retina, and proposed that it acts on gene transcription that the pineal gland and the retina have in common. The first papers on epitalon appeared in 2000.

Epitalon is a common name rather than an approved generic name, and products sold under it may contain the free peptide (CAS 307297-39-8) or its acetate salt (CAS 307297-40-1, 450.40 g/mol), which the FDA treats as two different substances. The literature is unusually concentrated: the FDA noted in 2026 that most pharmacological studies of epitalon were run and published by Khavinson's group, and two of the papers submitted to it, including the 2007 study in older people, were published only in Russian.

How it is thought to work

Khavinson's group attributes three main effects to epitalon: switching on telomerase, the enzyme that rebuilds the protective ends of chromosomes (telomeres); restoring the night-time rise of melatonin from the pineal gland; and antioxidant activity. How it would do any of this in the body is unknown. The FDA's 2026 review found no pharmacokinetic data in humans, so it is not known how much reaches the blood or for how long.

The telomerase finding comes from cell culture. In 2003 the group reported that epitalon switched on telomerase and lengthened telomeres in human fetal lung cells that normally lack the enzyme. In 2025 an independent team at Brunel University London reproduced this in two types of normal human cells over three weeks, and also found longer telomeres in two breast-cancer cell lines, where the lengthening ran mainly through a route that does not need telomerase (ALT). No published study has measured telomere length in people given epitalon.

The melatonin idea comes from monkeys and from small human studies. In a 2001 study of 12 female rhesus monkeys, six old and six young with three per treatment group, ten days of injections raised evening melatonin more than fourfold in the old animals and restored their daily cortisol rhythm, while melatonin did not change in the young ones. In a laboratory study on isolated rat pineal glands, however, epitalon did not increase melatonin release, and the FDA concluded that the way epitalon affects melatonin in the body remains unknown.

Is epitalon approved?

No. The EMA has not authorised any medicine containing epitalon, it has no monograph in the European Pharmacopoeia, and the FDA's 2026 review found no approved product in the UK, Canada, Australia or the European countries it checked, among them Belgium, Germany and France. In the Netherlands it is not a registered medicine, so it may not be sold or promoted for use in people; our shop sells it as research material only.

In the United States the question is whether pharmacies may compound it. The FDA's 2026 review was limited to insomnia, the only proposed use it found enough information to assess. On 24 July 2026 its Pharmacy Compounding Advisory Committee recommended adding epitalon to the list of bulk substances that pharmacies may use for compounding: seven members voted in favour and one abstained, against the advice of FDA staff. The vote is advice only, the FDA makes the final decision, and none had been published when this page was checked in October 2026. Even then, a compounded product would not be an approved drug.

• September 2010: the FDA granted epitalon an orphan-drug designation for retinitis pigmentosa; it was withdrawn in January 2016.
• 29 September 2023: the FDA placed epitalon in Category 2 of its compounding list, for substances that may pose significant safety risks, citing possible immune reactions, aggregation and peptide impurities, and the lack of safety data.
• April 2026: the two nominations having been withdrawn, the FDA's Category 2 page no longer listed epitalon in that category but among the withdrawn nominations.
• 12 May 2026: FDA staff evaluated epitalon on their own initiative and recommended against adding it: not well characterised, no evidence of effect in insomnia, no clinical safety data, and a theoretical cancer concern because it activates telomerase.
• 24 July 2026: the advisory committee voted to recommend it for insomnia anyway; no final FDA decision by October 2026.

What the research shows

Most of the evidence comes from cells and animals, and nearly all of it from Khavinson's network. The human studies of epitalon itself are few and small, mostly measured biomarkers rather than health outcomes, and were run by the group that developed it; no independent team has repeated any of them. The main findings:

• Mice (Biogerontology 2003): 54 female mice per group received epitalon or saline for five days a month from the age of three months until death. Average lifespan was unchanged; maximum lifespan was 12.3% longer and leukaemia six times rarer, while the overall tumour rate did not differ. The FDA notes that all three mouse lifespan studies by the group used females only and a single fixed dose.
• Night-shift workers (Ivko et al., 2021): of 75 women aged 40 to 50, mostly working nights, the 40 with low urinary levels of a melatonin breakdown product were split into two groups of 20 and given an epitalon or a saline spray under the tongue for 20 days. In the epitalon group the urinary level rose 1.7-fold, to the normal level for their age according to the authors. They also reported a better 'psycho-emotional and general physical condition' in 83% against 25% without saying how it was measured. Blinding was not described, sleep was not measured and no safety data were reported; a short 2021 report by the same authors on clock genes appears to describe the same women.
• Retinitis pigmentosa (Neuro Endocrinol Lett 2002): 162 patients aged 18 to 72 with this inherited eye disease received epitalon injections next to the eye for 10 days, and a comparison group of 46 received the standard drugs of the time instead of a placebo. The authors reported a positive clinical effect in 90% of cases; how patients were allocated, and whether anyone was blinded, is not clearly described.
• Older adults (Korkushko et al., 2007): a small study reported that epitalon raised night-time melatonin, mainly in people whose levels were low to begin with. According to a 2026 review, 15 older people received epitalon, 15 the extract and 10 a placebo. The paper was published only in Russian, and the FDA could not find an English version.
• Epithalamin, not epitalon: in 266 older people followed for six to eight years (Neuro Endocrinol Lett 2003), the authors reported mortality 1.6 to 1.8 times lower with the pineal extract than in controls, and 4.1 times lower with yearly courses of the extract plus the thymus extract thymalin. The abstract describes no placebo, blinding or method of allocation. Two later reports from the same network on older heart patients, which may share participants, also described lower mortality with the extract. None of these results can be credited to epitalon.
• Not studied: no trial has tested epitalon against placebo for sleep, ageing or any disease.

Epitalon or epithalamin?

The two names are easily confused and are often used interchangeably online, but they are different substances. Epithalamin is a mixture of peptides extracted from cattle pineal glands; epitalon is one synthetic tetrapeptide modelled on it. The FDA treats them separately, and its own substance register does not list epithalamin as another name for epitalon.

The difference matters because the most striking human results come from the extract: the mortality figures from St Petersburg and Kyiv, and several of the melatonin studies in older people, used epithalamin. The human studies of epitalon itself are smaller, shorter and used much lower amounts than the ranges common online; the Dosage tab lists them. A second confusion is chemical: research products may contain the free peptide or its acetate salt, and the certificates of analysis submitted to the FDA named one form in the title and gave the molecular formula or weight of the other.

Side effects and safety

There are no human safety data worth the name. The FDA's 2026 review found no clinical study that assessed the safety of epitalon, no pharmacokinetic data in people and no reports in its adverse-event database (FAERS) up to 8 December 2025. The small studies from Khavinson's network reported no side effects but did not describe how they looked for them, and the night-shift study reported no safety data at all.

Animal toxicology is thin as well. There are no acute, repeated-dose or reproductive toxicity studies, only small tests at a single dose level that found no increase in chromosome damage in mice. The mouse lifespan studies found fewer tumours, not more, but the FDA judged them too limited to rule out a cancer risk: females only, one fixed dose and, in the 2003 study, at most about 22 weeks of treatment in total. Because epitalon activates telomerase and long telomeres are associated with a higher cancer risk, the FDA concluded that it has carcinogenic potential on mechanistic grounds, and the 2025 Brunel study found telomeres lengthening in breast-cancer cells too. For injected products the FDA also flagged possible immune reactions caused by aggregates and peptide impurities.

Frequently asked questions

Does epitalon lengthen telomeres in humans?

That has not been shown. Epitalon switched on telomerase and lengthened telomeres in cultured human cells in 2003, and an independent British team confirmed this in normal cells in 2025. But no study has measured telomere length in people given epitalon, and the same 2025 study found longer telomeres in breast-cancer cells as well.

Is epitalon the same as epithalamin?

No. Epithalamin is a mixture of peptides extracted from cattle pineal glands; epitalon is a single synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed from its amino-acid composition. The FDA treats them as different substances. The human mortality figures often quoted for epitalon were obtained with epithalamin.

Has the FDA approved epitalon?

No. In July 2026 FDA advisers voted to recommend that US pharmacies be allowed to compound it for insomnia, against the advice of FDA staff, who had found no evidence that it works for insomnia and no human safety data. The vote is advice only; the FDA had made no final decision by October 2026, and a compounded product would still not be an approved drug.

Is epitalon legal in the Netherlands?

Epitalon is not a registered medicine in the Netherlands, and the EMA has authorised no medicine containing it, so it may not be sold, advertised or supplied for use in people. Buying and selling it as research material is a different status, which our guide on research-use-only products in the Netherlands explains.

Is epitalon banned in sport?

Epitalon is not named on the WADA Prohibited List, but that does not make it allowed. Class S0 bans, at all times, any substance that is not covered elsewhere on the list and has no current approval for human therapeutic use from any government health authority, and no such approval for epitalon has been found. The 2027 list, in force from 1 January 2027, names peptides explicitly as an example of S0. The Dutch anti-doping rules apply the same list; see our guide on peptides and the doping list.

Is epitalon safe?

Nobody knows. No study has assessed its safety in people: the few small human studies did not say how side effects were recorded, and the FDA found no adverse-event reports up to December 2025. Animal toxicity testing is limited, and because epitalon activates telomerase, the FDA considers a cancer risk possible on theoretical grounds.

Storage and handling

Store according to product-label instructions and batch handling notes. Lyophilized research peptides are commonly kept dry, protected from light, and handled with clean laboratory technique.

References

Checked against these sources on 28 October 2026.

Related peptides